DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s Net Worth

$2.05 Billion

Who is DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)?

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) has an estimated net worth of $2.05 Billion. This is based on reported shares across multiple companies, which include Fractyl Health, Inc., RHYTHM PHARMACEUTICALS, INC., Dicerna Pharmaceuticals Inc, Invuity, Inc., DYNAVAX TECHNOLOGIES CORP, XERIS PHARMACEUTICALS INC, ARENA PHARMACEUTICALS INC, Invitae Corp, Auspex Pharmaceuticals, Inc., Fibrocell Science, Inc., TriVascular Technologies, Inc., REGENXBIO Inc., CONSTELLATION PHARMACEUTICALS INC, NeurogesX Inc, Oncology Institute, Inc., Nkarta, Inc., Revolution Medicines, Inc., Kiniksa Pharmaceuticals, Ltd., DA32 Life Science Tech Acquisition Corp., RIGEL PHARMACEUTICALS INC, Editas Medicine, Inc., eHealth, Inc., Singular Genomics Systems, Inc., Nivalis Therapeutics, Inc., CareMax, Inc., Shockwave Medical, Inc., Aclaris Therapeutics, Inc., Vanda Pharmaceuticals Inc., Generation Bio Co., ANTARES PHARMA, INC., Edgewise Therapeutics, Inc., Nuvalent, Inc., AERIE PHARMACEUTICALS INC, AVADEL PHARMACEUTICALS PLC, Axogen, Inc., Mirum Pharmaceuticals, Inc., ARVINAS INC., Schrodinger, Inc., AdaptHealth Corp., Neos Therapeutics, Inc., Loxo Oncology, Inc., NeuroMetrix, Inc., GRAYBUG VISION, INC., Acutus Medical, Inc., Xilio Therapeutics, Inc., Larimar Therapeutics, Inc., Terns Pharmaceuticals, Inc., Cyclacel Pharmaceuticals, Inc., Syros Pharmaceuticals, Inc., Recro Pharma, Inc., CATALYST BIOSCIENCES, INC., CytomX Therapeutics, Inc., Mallinckrodt plc, CAS MEDICAL SYSTEMS INC, PROTEON THERAPEUTICS INC, AveXis, Inc., SteadyMed Ltd., Cabaletta Bio, Inc., Annexon, Inc., aTYR PHARMA INC, LUMOS PHARMA, INC., ALIMERA SCIENCES INC, Black Diamond Therapeutics, Inc., Ignyte Acquisition Corp., Homology Medicines, Inc., Werewolf Therapeutics, Inc., STREAMLINE HEALTH SOLUTIONS INC., Frequency Therapeutics, Inc., Oncorus, Inc., Audentes Therapeutics, Inc., AUXILIUM PHARMACEUTICALS INC, Talon Therapeutics, Inc., NxStage Medical, Inc., PepGen Inc., HI TECH PHARMACAL CO INC, DUSA PHARMACEUTICALS INC, PAR PHARMACEUTICAL COMPANIES, INC., Frazier Lifesciences Acquisition Corp, ARS Pharmaceuticals, Inc., ANADYS PHARMACEUTICALS INC, XENOPORT INC, ISTA PHARMACEUTICALS INC, Somaxon Pharmaceuticals, Inc., SALIX PHARMACEUTICALS LTD, MEDICINES CO /DE, NITROMED INC, VIA Pharmaceuticals, Inc., EMAGEON INC, THIRD WAVE TECHNOLOGIES INC /WI, INSPIRE PHARMACEUTICALS INC, Avalanche Biotechnologies, Inc., and MGI PHARMA INC.

SEC CIK

DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s CIK is 0001009258

Past Insider Trading and Trends

2006 was DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s most active year for acquiring shares with 128 total transactions. DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s most active month to acquire stocks was the month of June. 2011 was DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s most active year for disposing of shares, totalling 196 transactions. DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s most active month to dispose stocks was the month of May. 2019 saw DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) paying a total of $153,189,988.50 for 19,599,914 shares, this is the most they've acquired in one year. In 2020 DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) cashed out on 87,434,254 shares for a total of $18,052,380.80, their largest year based on trade value.